Suggested remit: To appraise the clinical and cost effectiveness of nivolumab within its marketing authorisation for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer.
Status In progress
Process STA 2018
ID number 1676

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
01 October 2020 - 29 October 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
13 February 2018 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance